WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tuesday, May 5, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2026 Earnings Snapshot through a link on the IDEXX website,.

Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Cancer Dx Panel with canine lymphoma detection helps clinicians investigate sooner and plan next steps with confidence.

Beacon Investment Advisory Services Inc. lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 11.9% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 62,951 shares of the company's stock after buying an additional 6,710 shares during the period. IDEXX Laboratories accounts for

Congress Asset Management Co. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 9,894.0% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 153,908 shares of the company's stock after purchasing an additional 152,368 shares during the quarter. Congress

Procyon Advisors LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,905 shares of the company's stock, valued at approximately $1,966,000. A number of other hedge funds have also recently

Achmea Investment Management B.V. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 319.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,769 shares of the company's stock after acquiring an additional 13,537 shares during the quarter.

Banco Bilbao Vizcaya Argentaria S.A. lifted its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 342.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,140 shares of the company's stock after purchasing an additional 10,943 shares during the quarter. Banco Bilbao Vizcaya

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.